Horizon Pharma PLC. Daily Stock Analysis

Daily Stock Analysis, HZNP, Horizon Pharma PLC, priceseries

Horizon Pharma PLC. Daily Stock Analysis
Stock Information
Open
99.05
Close
98.64
High
100.69
Low
98.38
Previous Close
99.38
Daily Price Gain
-0.74
YTD High
109.67
YTD High Date
Jan 4, 2022
YTD Low
83.42
YTD Low Date
Jan 24, 2022
YTD Price Change
-9.32
YTD Gain
-8.63%
52 Week High
120.54
52 Week High Date
Nov 1, 2021
52 Week Low
79.81
52 Week Low Date
Mar 29, 2021
52 Week Price Change
11.87
52 Week Gain
13.68%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 20. 2017
10.84
Jul 27. 2017
12.82
26 Trading Days
18.28%
Link
LONG
Sep 27. 2017
12.51
Oct 16. 2017
13.61
13 Trading Days
8.79%
Link
LONG
Feb 28. 2018
14.58
Mar 13. 2018
15.34
9 Trading Days
5.21%
Link
LONG
May 11. 2018
14.25
Jun 25. 2018
17.18
30 Trading Days
20.57%
Link
LONG
Aug 7. 2018
18.16
Aug 23. 2018
19.98
12 Trading Days
10.01%
Link
LONG
Jan 31. 2019
21.49
Feb 19. 2019
22.80
12 Trading Days
6.11%
Link
LONG
Dec 12. 2019
32.84
Jan 6. 2020
35.53
14 Trading Days
8.19%
Link
LONG
Apr 14. 2020
31.56
Jun 3. 2020
48.94
35 Trading Days
55.07%
Link
LONG
Jun 18. 2020
48.43
Jul 13. 2020
55.67
16 Trading Days
14.95%
Link
LONG
Jul 28. 2020
59.28
Aug 24. 2020
73.48
19 Trading Days
23.95%
Link
LONG
Feb 1. 2021
77.04
Feb 22. 2021
84.88
14 Trading Days
10.18%
Link
Company Information
Stock Symbol
HZNP
Exchange
NasdaqGS
Company URL
http://www.horizonpharma.com
Company Phone
011-353-1-772-2100
CEO
Timothy P. Walbert
Headquarters
-
Business Address
CONNAUGHT HOUSE, 1ST FLOOR, 1 BURLINGTON ROAD, DUBLIN, IRELAND 4
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001492426
About

Horizon Pharma Plc engages in the research, development, and market of pharmaceutical products. Its medicines intend to treat arthritis, inflammation, and orphan diseases. It distributes under the following brands: Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid, Ravicti, Rayos, and Vimovo. The company was founded on December 20, 2011 and is headquartered in Dublin, Ireland.

Description

Horizon Pharma Public Limited Company, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally. The company's marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; PROCYSBI for the treatment of nephropathic cystinosis; QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients; and KRYSTEXXA to treat chronic refractory gout. Its products also include RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and multiple other indications; DUEXIS to treat signs and symptoms of osteoarthritis and rheumatoid arthritis; MIGERGOT for the treatment of vascular headache; PENNSAID 2% to treat pain of osteoarthritis of the knees; and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The company has collaboration agreements with Fox Chase Cancer Center to study ACTIMMUNE in combination with PD-1/PD-L1 inhibitors for use in the treatment of various forms of cancer; and Alliance for Lupus Research (ALR) to study the effect of RAYOS on the fatigue experienced by systemic lupus erythematosus (SLE) patients. Horizon Pharma Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading